β-RELIEVED - REsponse in Acute fLare and In prEVEntion of episoDes of Re-flare in Gout - Extension 3 (E3)
NCT ID: NCT01470989
Last Updated: 2021-07-09
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
136 participants
INTERVENTIONAL
2011-11-30
2013-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Canakinumab in the Treatment of Acute Gout Flares and Prevention of New Flares in Patients Unable to Use Non-steroidal Anti-inflammatory Drugs (NSAIDs) and/or Colchicines Including a 12 Week Extension and a 1 Year Open-label Extension Study.
NCT01080131
Canakinumab in the Treatment of Acute Gout Flares and Prevention of New Flares in Patients Unable to Use Non-steroidal Anti-inflammatory Drugs (NSAIDs) and/or Colchicine Including a 12 Weeks Extension and an Open-label 48 Weeks Extension Study
NCT01029652
Safety & Efficacy of Canakinumab (ACZ885) in Patients With Frequent Flares for Whom Nonsterodial Anti-Inflammatory Drug (NSAIDs) and/ or Colchicine Are Contraindicated, Not Tolerated or Ineffective
NCT01362608
Safety and Efficacy of Canakinumab Prefilled Syringes in Frequently Flaring Acute Gouty Arthritis Patients
NCT01356602
Canakinumab in the Treatment of Gouty Arthritis Flare(s) and Prevention of New Flares in Patients With Chronic Kidney Disease
NCT01593527
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
canakinumab
canakinumab 150 mg s.c.
ACZ885
canakinumab 150 mg s.c., given on demand upon new flares
Triamcinolone acetonide 40 mg
Participants received 40 mg intramuscular (IM)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
ACZ885
canakinumab 150 mg s.c., given on demand upon new flares
Triamcinolone acetonide 40 mg
Participants received 40 mg intramuscular (IM)
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients treated with canakinumab in the core studies or subsequent extensions
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Novartis Pharmaceuticals
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Novartis Pharmaceuticals
Role: STUDY_DIRECTOR
Novartis Pharmaceuticals
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Novartis Investigative Site
Anniston, Alabama, United States
Novartis Investigative Site
Mobile, Alabama, United States
Novartis Investigative Site
Norwalk, California, United States
Novartis Investigative Site
Pasadena, California, United States
Novartis Investigative Site
San Diego, California, United States
Novartis Investigative Site
Tustin, California, United States
Novartis Investigative Site
Clearwater, Florida, United States
Novartis Investigative Site
Jupiter, Florida, United States
Novartis Investigative Site
Decatur, Georgia, United States
Novartis Investigative Site
Overland Park, Kansas, United States
Novartis Investigative Site
Topeka, Kansas, United States
Novartis Investigative Site
Wichita, Kansas, United States
Novartis Investigative Site
Metairie, Louisiana, United States
Novartis Investigative Site
Opelousas, Louisiana, United States
Novartis Investigative Site
Flint, Michigan, United States
Novartis Investigative Site
Troy, Michigan, United States
Novartis Investigative Site
Jackson, Mississippi, United States
Novartis Investigative Site
Jackson, Mississippi, United States
Novartis Investigative Site
Missoula, Montana, United States
Novartis Investigative Site
Omaha, Nebraska, United States
Novartis Investigative Site
Freehold, New Jersey, United States
Novartis Investigative Site
Hickory, North Carolina, United States
Novartis Investigative Site
Dayton, Ohio, United States
Novartis Investigative Site
Willoughby Hills, Ohio, United States
Novartis Investigative Site
Charleston, South Carolina, United States
Novartis Investigative Site
Charleston, South Carolina, United States
Novartis Investigative Site
Columbia, South Carolina, United States
Novartis Investigative Site
Varnville, South Carolina, United States
Novartis Investigative Site
Bristol, Tennessee, United States
Novartis Investigative Site
Clarksville, Tennessee, United States
Novartis Investigative Site
Johnson City, Tennessee, United States
Novartis Investigative Site
Danville, Virginia, United States
Novartis Investigative Site
Newport News, Virginia, United States
Novartis Investigative Site
Darlinghurst, New South Wales, Australia
Novartis Investigative Site
St. John's, Newfoundland and Labrador, Canada
Novartis Investigative Site
St. John's, Newfoundland and Labrador, Canada
Novartis Investigative Site
St. John's, Newfoundland and Labrador, Canada
Novartis Investigative Site
Sainte-Foy, Quebec, Canada
Novartis Investigative Site
Tallinn, , Estonia
Novartis Investigative Site
Tallinn, , Estonia
Novartis Investigative Site
Augsburg, , Germany
Novartis Investigative Site
Löhne, , Germany
Novartis Investigative Site
Magdeburg, , Germany
Novartis Investigative Site
Valmiera, , Latvia
Novartis Investigative Site
Kaunas, , Lithuania
Novartis Investigative Site
Klaipėda, , Lithuania
Novartis Investigative Site
Šiauliai, , Lithuania
Novartis Investigative Site
Vilnius, , Lithuania
Novartis Investigative Site
Vilnius, , Lithuania
Novartis Investigative Site
Moscow, , Russia
Novartis Investigative Site
Petrozavodsk, , Russia
Novartis Investigative Site
Saint Petersburg, , Russia
Novartis Investigative Site
Yaroslavl, , Russia
Novartis Investigative Site
Yekaterinburg, , Russia
Novartis Investigative Site
Uzhhorod, , Ukraine
Novartis Investigative Site
Zaporizhzhya, , Ukraine
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2011-003414-17
Identifier Type: -
Identifier Source: secondary_id
CACZ885H2357E3
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.